Intravenous drug use and the heterosexual transmission of the human immunodeficiency virus
Women, and men who deny homosexual activity, account for slightly more than one third (3,929/7,696) of the cases of acquired immunodeficiency syndrome (AIDS) in New York City through September 1986.1 This percentage has been rising during the course of the epidemic. Intravenous (IV) drug users account for more than half (2,261/3,929) of these heterosexual cases, and an additional 134 cases have occurred in persons known to be heterosexual partners of IV drug users. The connections between AIDS, IV drug use, and the heterosexual transmission of the human immunodeficiency virus (HIV) pose one of the more difficult public health challenges facing the city and the country. In this paper we review data relevant to two questions: potential heterosexual transmission among IV drug users, and potential transmission from IV drug users to heterosexual partners who do not inject drugs.
KeywordsHuman Immunodeficiency Virus Drug User York City Human Immunodeficiency Virus Infection Acquire Immunodeficiency Syndrome
Unable to display preview. Download preview PDF.
- 1.New York City Department of Health AIDS Surveillance, September 1986.Google Scholar
- 3.Novick DM, Kreek M J, Des Jarlais DC, et al: Antibody to LAV among intravenous drug users: Historical, therapeutic and ethical aspects, in Harris L (ed): Problems of Drug Dependence 1985: Proceedings of the 47 th Annual Scientific Meeting. NID A Research Monograph 67. Washington, DC, The Committee on Problems of Drug Dependence, Inc, 1985, pp 318–320.Google Scholar
- 4.Cohen H, Marmor M, Des Jarlais DC, et al: Risk factors for HTLV-III/ LAV seropositivity among intravenous drug users. Presented at the International Conference on the Acquired Immunodeficiency Syndrome (AIDS), Atlanta, Ga, April 14–17, 1985.Google Scholar
- 5.Weiss SH, Ginzburg HM, Goedert JJ, et al: Risk for HTLV-III exposure and AIDS among parenteral drug abusers in New Jersey. Presented at the International Conference on the Acquired Immunodeficiency Syndrome (AIDS), Atlanta, Ga, April 14–17, 1985.Google Scholar
- 6.Schoenbaum EE, Selwyn PA, Klein RS, et al: Prevalence of and risk factors associated with HTLV-III/LAV antibodies among intravenous drug abusers in a methadone program in New York City. Presented at the International Conference on AIDS, Paris, France, June 23–25, 1986.Google Scholar
- 8.New York City Department of Health Bureau of Health Statistics, 1986.Google Scholar
- 9.Wish ED, Johnson BD: The impact of substance abuse on criminal careers, in Blumstein A, Cohen J, Visher CA (eds): Criminal Careers and Career Criminals. Washington, DC, National Academy Press, 1986, vol 2, pp 52–58.Google Scholar
- 10.Wallace JI, Christonikos N, Merlink R, et al: HTLV-III/LAV exposure in New York City prostitutes. Presented at the International Conference on AIDS, Paris, France, June 23–25, 1986.Google Scholar
- 11.New York City Department of Health AIDS Surveillance, 1986.Google Scholar
- 12.Rabkin CS, Thomas PA, Jaffe H, et al: Prevalence of antibody to HTLV-III/LAV in a population attending a sexually transmitted disease clinic. Sex Transm Dis 1986; 13:80–83.Google Scholar
- 14.Friedman SR, Des Jarlais DC, Goldsmith DS: An overview of current AIDS prevention efforts aimed at intravenous drug users. J Drug Issues (in press).Google Scholar
- 15.Friedman SR, Des Jarlais DC, Sotheran JL, et al: AIDS and self-organization among intravenous drug users. Int J Addict (in press).Google Scholar